참여 물질
| 역할 | 이름 | HCID | 투입량 |
|---|
| 반응물 | 1-Heptyne | HCID 12350 | — |
| 반응물 | Leukotriene B4 | HCID 5280492 | — |
| 반응물 | (-)-Glycidol | HCID 6973630 | — |
| 반응물 | L-Ascorbic Acid | HCID 54670067 | — |
| 용매 | Diethyl Ether | HCID 3283 | — |
| 생성물 | a-[(tetrahydro-2H-pyran-2-yl)oxy]dec-4-yn-2(R)-ol | HCID 14464847 | — |
반응 단계
The starting material for the process of this invention, compound 2, can be prepared as described in Nicolaou, K. C. et al., "A General and Stereocontrolled Total Synthesis of Leukotriene B4 and Analogues," J. Am. Chem. Soc., 106, 3548 (1984) or Hanson, R. M. and Sharpless, K. B., J. Org. Chem., 51 1922 (1986). Briefly, optically active (S)-glycidol THP ether is prepared from ascorbic acid as disclosed in Takano, S., Numata, H., Ogasawara, K., Heterocycles, 19, 237 (1982) and Baldwin, J. J., Raab, A. W., Mensler, K., Arison, B. H., McClure, D. E., J. Org. Chem., 43, 4876 (1978). The ether is reacted (-78°-25° C.) with two equivalents of the anion of 1-heptyne (1.0 equiv. of n-BuLi, 1.0 equiv. of TMEDA and THF, -78° C.) to afford a-[(tetrahydro-2H-pyran-2-yl)oxy]dec-4-yn-2(R)-ol which is then silylated (t-BuPh2SiCl, imidazole, DMF) to, compound 2.
출처 및 근거
| DOI | 10.6084/m9.figshare.5104873.v1 |
|---|
| 특허 번호 | US04873024 |
|---|
| 출처 데이터셋 | uspto-grants-1989_10 |
|---|
| ORD ID | ord-491ea872368f4a6580fbc8c0e583bfc3 |
|---|
| 출처 메모 | uspto-grants-1989_10 |
|---|